Rani raises cash for 'holy grail' of oral formulations for biologics
This article was originally published in Scrip
Rani Therapeutics completed a Series B funding round to finance technology that's designed to convert biologics into pills, which could give pharmaceutical companies a competitive advantage and extend the patent lives of blockbuster injectable drugs, according to the company's chairman and CEO Mir Imran.
You may also be interested in...
The company has linked up with Rani Therapeutics to develop a simple-to-swallow capsule that is able to provide an alternative to current injectable therapies for hemophilia A.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.